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ABSTRACT 
The multidrug resistance P-glycoprotein (P-gp) is characterised by the ability to bind and/or 
transport an astonishing array of drugs. This poly-specificity is imparted by at least four 
pharmacologically distinct binding sites within the transmembrane domain. Whether or not these 
sites are spatially distinct has remained unclear. Biochemical and structural investigations have 
implicated a central cavity as the likely location for the binding sites. In the present investigation, a 
number of contact residues that are involved in drug binding were identified through biochemical 
assays using purified, reconstituted P-gp. Drugs were selected to represent each of the four 
pharmacologically distinct sites. Contact residues important in rhodamine123 binding were 
identified in the central cavity of P-gp. However, contact residues for the binding of vinblastine, 
paclitaxel and nicardipine were located at the lipid-protein interface rather than the central cavity. A 
key residue (F978) within the central cavity is believed to be involved in coupling drug binding to 
nucleotide hydrolysis. Data observed in this investigation suggest the presence of spatially distinct 
drug binding sites connecting through to a single translocation pore in the central cavity. 
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1. INTRODUCTION 
P-glycoprotein (P-gp) is a drug efflux pump and a member of the ATP Binding Cassette (ABC) 
family of proteins within the B-subfamily [1]. Its expression in cancer cells confers a drug resistant 
phenotype [2, 3] by preventing the accumulation of chemotherapy agents to cytotoxic levels. P-gp is 
capable of binding and/or transporting an astonishing number of chemically distinct compounds, 
whose only similarities include hydrophobicity, a planar ring system and often, the presence of a 
cationic nitrogen moiety [4-6]. This poly-specificity exhibited by P-gp remains an enigmatic feature 
that has eluded a molecular description to date. 
Numerous efforts have been made to explain the complex interactions of drugs with P-gp. The 
standard approach was to combine drugs and ascertain whether they interacted in a competitive (one 
site) or non-competitive (>one site) fashion [7-10]. For example, the extent and kinetics of transport 
were measured for the fluorescent drugs rhodamine123 and Hoechst33342 alone, or in combination 
[10]. The authors demonstrated positively co-operative transport for the two probes, which indicates 
the presence of at least two transport-competent sites. The authors developed the nomenclature of H 
(Hoechst) and R (Rhodamine123) sites on the protein. Subsequent studies revealed the presence of 
a third (P) site that was capable of transporting prazosin [11]. In addition, these studies 
demonstrated that some sites are capable of binding both substrates and inhibitors. 
Drug-P-gp interactions have also been investigated with photo-activate drug analogues that 
covalently cross-link to P-gp at their interaction site, enabling the identification of possible binding 
sites [12-15]. Subsequent proteolytic or chemical cleavage was used to generate peptide fragments 
for analysis of the regions or amino acids that had been covalently modified. Many studies observed 
cross-linking of the probes to both the N- and C-terminal halves of the transmembrane domain 
(TMD). This was initially interpreted as proof of multiple binding sites, but it is also possible that 
both halves of the TMD could contribute to a single site. More convincing proof of the multiple-site 
hypothesis was obtained in an investigation using the prazosin photoaffinity analogue [125I]IAAP in 
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the presence of the modulator cis(Z)-flupentixol [16]. The photoaffinity probe labelled two sites on 
P-gp (N- and C-terminal) and the modulator only displaced labelling at the C-terminal site. 
Another strategy involved the use of classical equilibrium and kinetic radioligand binding studies in 
order to assign competitive and allosteric interactions between drug combinations [7, 17]. This 
strategy enabled the demonstration of at least four pharmacologically distinct drug binding sites on 
P-gp. The sites are considered “distinct” since two drugs displayed non-competitive interactions in 
binding assays. The spatial relationship between distinct sites is not determined by this approach. 
Moreover, some of these sites were shown to bind transported drugs only, one bound only 
modulators and another interacted with both transported substrates and modulators. Therefore, not 
only are there multiple sites for binding, but the outcome (i.e. transport or inhibition) for the 
interaction is likely dependent on the physical and chemical properties of drugs. 
The consensus emerging from these different investigative approaches is that P-gp comprises a 
large domain to support drug interaction and that this domain may be divided into specialised 
binding sites for specific, chemically related compounds. According to the Jardetzky model [18], 
the binding sites undergo alternating access between the intra- and extra-cellular environments. 
Events at the nucleotide binding domains (NBDs) drive the transition of binding sites between these 
conformations. 
A key issue to be resolved is the precise location of the drug binding domain, its constituent sites 
and the molecular interactions that govern binding. Structural models of mouse P-gp suggested that 
the central cavity of the protein was the likely region for drug binding [19, 20]. Moreover, the 
central cavity is lined by a number of TM helices that have been widely implicated in the 
interaction of drugs with P-gp during the translocation process [12, 16, 21]. This investigation 
proposes that individual drug binding sites lie within this central cavity and a number of amino-acid 
residues have been selected with the aim of identifying the locations of binding sites within the 
domain. Drugs that are known to bind at one of each of the four pharmacologically distinct binding 
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sites were used to define which residues are involved in their interaction. This systematic analysis 
of the mutant isoforms has identified specific “contact residues” within each of the four 
pharmacological sites of drug binding to P-gp.  
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2. MATERIALS & METHODS 
2.1.Materials 
The tissue culture media Insect-Xpress and Ex-Cell 405 (powder) were purchased from Lonza 
(Gordon, NSW) and Sigma-Aldrich (Castle Hill, NSW) respectively. Foetal Bovine Serum (heat 
inactivated) was obtained from Bovogen (East Keilor, Vic) and dodecyl--D-maltoside from 
Anatrace (Ohio, USA). The E coli total lipid extract was purchased from Avanti Polar Lipids 
(Alabama, USA) and the Ni-NTA HisBind resin from Merck (Bayswater, Vic).BioBead SM-2 
resin was obtained from BioRad (Gladesville, NSW) and PD-10 (8.3ml) gel permeation columns 
from VWR (Tingalpa, Qld) Cholesterol, imidazole, disodium adenosine triphosphate, vinblastine 
sulphate, nicardipine, paclitaxel, rhodamine123 and dimethyl-sulfoxide were all purchased from 
Sigma-Aldrich (Castle Hill, NSW). The horse-radish-peroxidase conjugated, mouse, anti-histidine 
monoclonal antibody was purchased from R&D Systems via BioScientific (Kirrawee, NSW). All 
general laboratory chemicals were of at least analytical grade and obtained from standard laboratory 
suppliers. 
 
2.2.Generation of mutant P-gp isoforms and production of recombinant baculovirus 
Mutations were introduced at 7 positions into a cysteine free, C-terminally His-tagged version of P-
gp [22] encoded in a baculovirus expression system compatible plasmid (pFastBac_MCHS; [23]). 
Single cysteine isoforms M197C (TM3), A311C (TM5), F769C (TM8), F951C (TM11) and V982C 
(TM12) were generated in the mammalian cell expression vector pcIneo_MCHS using QuikChange 
mutagenesis. These isoforms were then sub-cloned into pFastBac_MCHS by BamHI/NotI mediated 
sub-cloning. Residues L65C (TM1) and F336C (TM6) were directly introduced into 
pFastBAC_MCHS using QuikChange mutagenesis. The fidelity of all mutagenesis and sub-cloning 
was confirmed by DNA sequencing across the entire coding sequence (SourceBiosciences, 
Nottingham, UK). pFastBac plasmids containing single cysteine isoforms were transformed into E. 
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coli DH10Bac competent cells and bacmid DNA isolated as previously described [24]. Bacmid 
DNA was verified by PCR amplification using M13 forward and reverse primers which span the 
integrated P-gp cDNA and all point mutations were confirmed by sequencing bacmid PCR 
products. Bacmid DNA was transfected into serum free Sf9 cells, and high titre viruses produced as 
described [24]. 
 
2.3.Expression, purification and reconstitution of P-gp mutants 
P-gp was expressed in Trichoplusia ni (High-Five) cells following infection with recombinant 
baculovirus containing the specific mutant isoform. High-5 cells were purchased from Invitrogen 
(via Thermo-Fisher Australia) and not used beyond passage 25. Typically, 1-2 x 106 High-Five cells 
were treated with recombinant baculovirus at a multiplicity of infection (MOI) of 2 and the cells 
were grown for a period of three days post-infection. Cells were subsequently harvested by 
centrifugation and the pellet stored at -80oC. Crude membranes were prepared from the cells using 
differential ultracentrifugation following cell disruption by nitrogen cavitation as previously 
described [22]. Membranes were stored at -80oC at a protein concentration of 30-50mg ml-1. 
P-gp was purified using immobilised metal affinity chromatography (IMAC) in a gravity based 
system, according to previously published methods with some modifications [22, 24]. The crude 
membranes (30-100mg) were suspended (5mg ml-1 protein) in solubilisation buffer supplemented 
with a 0.4% (w v-1) lipid mixture (4:1 ratio of E coli extract:cholesterol) and 2% (w v-1) dodecyl--
D-maltoside (DDM). The DDM solubilised P-gp was mixed by slow stirring with Ni-NTA 
HisBind Resin (750l per 100mg starting membrane) for 90 minutes at 4oC. Following binding to 
the resin, protein was washed sequentially with 5 bed-volumes (bv) of chromatography buffer 
(pH8.0) containing 20, 40 and 80mM imidazole. The chromatography buffer (pH6.8) was 
supplemented with 0.1% (w v-1) DDM and 0.1% (w v-1) lipid mixture. P-gp was eluted with 
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500mM imidazole and reconstituted using detergent adsorption to SM-2 BioBeads as previously 
described [22]. 
 
2.4.Measurement of ATP hydrolysis by mutant P-gp isoforms 
ATP hydrolysis was determined by measurement of the rate of inorganic phosphate liberation by P-
gp containing proteoliposomes using a modified colorimetric assay [24, 25]. In order to determine 
the Michaelis-Menten parameters, proteoliposomes (0.1-0.5g protein per point) were incubated 
with ATP (0-1.75mM) either in the presence of 10M nicardipine (i.e. stimulated activity) or with 
the solvent DMSO (i.e. basal activity). In order to investigate the potency of drugs to stimulate ATP 
hydrolysis, activity was measured as a function of added drug concentration (10-9 to 10-4 M) in the 
presence of 2 mM ATP. Following incubation (40 minutes, 37oC), the reaction was stopped by the 
addition of SDS and the inorganic phosphate was measured following formation of a complex with 
molybdate. Once the colour-forming reaction was complete, the absorbance at =750nm was 
measured for all samples using an iMark Microplate reader. The amount of phosphate liberated was 
determined from extrapolation of absorbance to a standard curve of inorganic phosphate (0-20nmol 
Pi). In all cases the activity was expressed as moles of Pi liberated per minute per mg of pure 
protein. 
The affinity for ATP (KM) and the maximal activity (VMAX) were obtained from non-linear 
regression of the hyperbolic relationship of activity (v) as a function of ATP concentration (S): 𝑣 =
(𝑉𝑀𝐴𝑋 × [𝑆]) (𝐾𝑀 + [𝑆])⁄ . 
The potency (EC50) and extent of stimulation of ATPase activity (v) were estimated by non-linear 
regression of the general dose-response relationship to plots of activity as a function of drug 
concentration ([D]):  𝑣 = 𝑣𝑖𝑛𝑖𝑡𝑖𝑎𝑙 + (𝑣𝑓𝑖𝑛𝑎𝑙 − 𝑣𝑖𝑛𝑖𝑡𝑖𝑎𝑙) (1 + 10
(𝑙𝑜𝑔10(𝐸𝐶50−[𝐷])))⁄ , where vinitial is the 
activity in the absence of drug and vfinal is the maximal activity observed. 
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2.5.Fluorescence based measurement of drug binding to P-gp  
Binding of drugs to purified, reconstituted P-gp was measured through the quenching of the 
fluorescence of endogenous tryptophan residues [26]. Purified P-gp preparations were subjected to 
buffer exchange (200mM NaCl, 20mM MOPS pH6.8, 5% (v v-1) glycerol, 0.1% (w v-1) DDM and 
0.1%(w v-1) lipid mixture) to remove the imidazole used during the elution phase of 
chromatography. This was done prior to reconstitution using PD-10 gel permeation columns 
according to the manufacturer’s instructions. Fractions containing purified P-gp in imidazole-free 
buffer were reconstituted as described earlier [24]. 
A minimum of 50g protein was added to a quartz-silica fluorescence cuvette in a total volume of 
1ml buffer (200mM NaCl, 20mM MOPS pH7.4). A fluorescence spectrum for the tryptophan 
residues was detected with excitation= 295±5nm and a emission range from 300-500nm (emission slit 
width = 5nm) at a rate of 120nm min-1. The range of drug concentrations (2-50M) was achieved 
by sequential addition from a concentrated stock in DMSO. The solvent concentration was 
maintained at 1% v v-1, which has previously been shown not to adversely affect P-gp function 
[27]. Emission spectra were recorded following 5 minutes incubation post-addition of drug. Spectra 
were also recorded following the sequential addition of the equivalent amount of solvent to 
ascertain whether fluorescence was affected. 
Where the addition of drug merely resulted in an alteration of the emission intensity at the max, the 
intensity value was plotted as a function of drug concentration. If the drug addition resulted in 
alteration of max, the extent of this wavelength shift was plotted as a function of drug 
concentration. In both cases, the secondary plot was hyperbolic and was fitted, by non-linear 
regression, with the following binding isotherm; 𝐵 = (𝐹𝑆𝑀𝐴𝑋[𝐷]) (𝐾𝐴𝑝𝑝 + [𝐷])⁄ . The change in 
fluorescence intensity or max reflected the extent of drug binding, the FSMAX refers to the maximal 
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change in fluorescence observed, KApp to the apparent binding affinity and [D] to the drug 
concentration. The FSMAX provides an approximation of the amount of drug bound to the protein. 
The KApp, reveals the affinity of drug interaction with the protein and an indication of the relative 
strength of binding.  
 
2.6.Statistical analyses 
All curve-fitting was done using non-linear least squares regression using GraphPad Prism 4 and an 
F-test was used for comparison of multiple curves. Comparison between multiple P-gp isoforms 
was performed using ANOVA with the Dunnett’s post-hoc test for significance. Statistically 
significant differences were defined where P<0.05 and all comparisons used at least three 
independent protein preparations. 
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3. RESULTS 
 
3.1.Expression and purification of P-gp isoforms 
A series of mutations was selected for investigation based on the frequency of reports implicating 
their involvement in P-gp function. The data involved mutagenesis [12-15], structural information 
[19], cysteine-directed mutagenesis [21, 28, 29] and mass spectroscopy [30]. The generation of 
recombinant baculovirus that produced expression of the P-gp isoforms was successful for seven 
single cysteine mutants and the cysteine-less (CL-P-gp) control (Figure 1). However, despite 
repeated attempts, expression of the F951C and F343C mutants was not achieved (data not shown). 
Figure 1b shows a representative SDS-PAGE profile of fractions obtained throughout the 
purification procedure for CL-P-gp. Contaminating proteins were found in the flow-through 
fractions, which correspond to unbound material, and the 20mM imidazole wash fractions. CL-P-gp 
was eluted in the 500mM imidazole fraction and the band demonstrates high purity protein at a 
molecular weight of ~140kDa. Western immuno-blotting was used to confirm that this protein was 
P-gp and that following BioBead mediated reconstitution, the protein was found in lipid containing 
fractions. The SDS-PAGE analysis was done for each protein preparation to confirm that the level 
of P-gp purity was sufficient for functional assays. Typical yields for CL and the single-cysteine 
mutant P-gp preparations was 0.2-0.6 mg L-1 insect cell culture. 
 
3.2.Functional properties of mutant P-gp isoforms 
Measurement of the basal (drug free) and drug-stimulated ATPase activity of P-gp provides a 
stringent assessment of the functional integrity of purified protein. ATPase activity was measured as 
a function of ATP concentration to generate the Michaelis-Menten parameters of affinity for 
nucleotide (KM) and the maximal activity (VMAX). Stimulation of ATP hydrolysis was measured in 
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the presence of the modulator nicardipine (10M). The VMAX for each mutant isoform under basal, 
and drug stimulated, conditions is shown in Figure 2. The cysteine-less (CL) isoform of P-gp was 
used as the control for all mutant isoforms since the cysteine insertion was done into this 
background. Moreover, CL-P-gp isoformsand has have previously been demonstrated to retain 
activity, based on several assay systems, that was qualitatively identical to the wild-type protein 
[22, 31, 32]. The subtle differences from wild-type protein involve minor quantitative changes only. 
The basal activity (VMAX = 386±36 nmol min-1 mg-1) of CL-P-gp was stimulated by 3.0±0.4 fold to 
a maximal activity of VMAX = 1048±103 nmol min-1 mg-1. The affinity for ATP was similar under 
basal (KM = 0.66±0.06 mM) and stimulated (KM = 0.85±0.28 mM) conditions. 
Of the 7 mutant isoforms examined only one (T769C) showed a perturbation of the basal ATPase 
activity, i.e. the activity in the absence of drug substrate.  For T769C this manifested as a 75% 
reduction in basal (VMAX = 92±19 nmol min-1 mg-1) compared to CL-P-gp. Despite this reduction in 
basal activity, T769C and all other isoforms had similar levels of nicardipine stimulated ATPase 
activity (682-1614 nmol min-1 mg-1, ANOVA p > 0.05) and similar degrees of stimulation (2.9-3.8 
fold, ANOVA p > 0.05). All isoforms also retained KM values for basal and drug-stimulated 
ATPase activity that were not statistically different from CL-P-gp control. Therefore, the cysteine 
insertion mutations used in the present investigation did not produce alterations in the protein that 
caused major functional perturbation. This validates their use in defining more subtle alterations in 
the interaction between drugs and P-gp. 
Figure 3 demonstrates the assays used in the characterisation of drug interaction with the various P-
gp mutant isoforms. Panel (a) provides dose-response analysis of the effects of nicardipine on ATP 
hydrolysis by CL-P-gp. The sigmoidal increase in ATPase activity was characterised by potency for 
nicardipine of EC50 = 1.10±0.41 M and a 2.0±0.3-fold stimulation of the activity, over the 
concentration range shown. The potency and degree of stimulation was assessed for all mutants 
with four “marker” drugs as shown in subsequent sections (tables 1-4). The four drugs nicardipine, 
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rhodamine123, vinblastine and paclitaxel were chosen since each of them bound to one of the four 
pharmacologically distinct binding sites previously described on P-gp [17].  
Stimulation of ATP hydrolysis involves an initial binding of drug and then subsequent 
conformational changes in the TMD to enable acceleration of the catalytic process. To provide 
further, and more direct, assessment of the binding between drug and P-gp, the tryptophan 
fluorescence assay was used [26]. The assay has been widely used to characterise novel 
substrates/modulators of P-gp and relies on the quenching (or its relief) of fluorescence from 
intrinsic tryptophan residues. Hydrophobic drugs, such as those used in this study, may undergo 
 stacking interactions with tryptophan residues and thereby alter the fluorescence emission 
spectrum. Alternatively, the binding of drug to P-gp may alter the local environment of the 
tryptophan (e.g. conformation or orientation) to alter its fluorescence spectrum. Figure 3(b-c) 
demonstrate the differential effects of nicardipine and vinblastine on the tryptophan emission 
spectrum of CL-P-gp. In the case of nicardipine (panel b), the maximal intensity of the emission 
spectrum was reduced in a dose-dependent manner. By contrast, the addition of vinblastine (panel 
c) caused a two-fold effect; namely a dose-dependent shift in the wavelength for maximal emission 
intensity (MAX) and a corresponding increase in the intensity of the spectrum. In either case, the 
magnitude of the shift in response was plotted as a function of the drug concentration to generate a 
binding isotherm. Figure 3(d) shows the binding isotherm for vinblastine interaction with CL-P-gp 
obtained from five independent preparations of purified protein. The isotherm displayed a 
hyperbolic increase in the spectral shift of FSMAX = 33±4 nm, which was defined by an apparent 
binding affinity of KApp = 6.8±0.8 M. 
 
Each of the mutant P-gp isoforms was assessed for the potency of the four “marker” drugs to 
stimulate ATP hydrolysis as shown in Figure 3(a). Those mutations that altered the potency of drug 
to stimulate ATP hydrolysis were then examined for their effect on drug binding using the 
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tryptophan fluorescence assay as shown in Figure 3(d). In addition, at least one mutation with no 
alteration in ATPase activity was selected for tryptophan fluorescence analysis, to validate that 
changes in the potency to stimulate ATPase activity are as a result of directly altered P-gp:drug 
interaction. From these two functional assays, we propose that any mutation that alters the potency 
to stimulate ATPase activity and tryptophan fluorescence (KApp) is having a direct involvement in 
drug binding and is a contact residue for that drug. A mutation that altered ATPase activity but did 
not alter tryptophan fluorescence (i.e. binding to P-gp) is likely to impacts the communication 
between domainsalter the inter-domain process involved in stimulating the rate of hydrolysis within 
the NBDs. Subsequent sections focus on identifying contact residues that facilitate drug binding at 
each of the four pharmacological sites on P-gp.  
 
3.3.Location of residues contributing to nicardipine binding to P-gp 
The dihydropyridine nicardipine is a widely used modulator of drug transport by P-gp and was 
shown to stimulate the basal rate of CL-P-gp by 2.0±0.3 fold, with a potency of 1.1±0.4 M (Table 
1). Nicardipine also stimulated the rate of ATP hydrolysis in all seven cysteine containing mutants 
to an extent identical to the CL-P-gp isoform (range 1.7-3.5 fold). However, three mutant isoforms 
displayed a significant alteration in the potency of nicardipine to stimulate ATP hydrolysis 
compared to the cysteine-less control. The potencies of A311C-P-gp (P<0.05) and T769C-P-gp 
(P<0.05) were reduced approximately 3-fold by the mutation; although, as described above, the 
maximal extent of stimulation was unaffected. The greatest alteration in potency to stimulate ATP 
hydrolysis was observed for F978C-P-gp, where the EC50 for potency to stimulate was increased to 
19.5±0.4 M. The other isoforms did not display potencies different to the CL-P-gp, which also 
indicates that the introduced mutations did not significantly affect the binding of nicardipine. 
In order to ascertain whether the potency alterations were due to a defect in nicardipine binding, or 
impaired inter-domain coupling, the tryptophan binding assay was undertaken. Nicardipine bound 
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to CL-P-gp with an apparent binding affinity of KApp = 43.4±3.5 M and a spectral shift of FSMAX = 
44±4 r.f.u (Table 1). The binding of nicardipine to P-gp was significantly impaired by the T769C 
mutation with a KApp value beyond the concentration of nicardipine that could be added to the assay 
system. Hence the KApp value was assigned a value of >100M (Table 1) and the binding capacity 
could also not be reliably estimated from the analysis. Amino acid 769 of P-gp was classified as a 
“contact-residue” for nicardipine and likely resides within its binding site. 
The A311C and F978C mutations also caused a significant alteration in the binding of nicardipine 
to P-gp. Unlike the T769C mutation, they caused 2-fold increase in the affinity of nicardipine 
binding to P-gp (Table 1). It is possible that the amino acids at these positions directly contribute to 
nicardipine binding and that the mutation of the endogenous residue to cysteine improved the 
binding affinity. Alternatively, the mutations caused new conformational transitions of the TMDs in 
response to nicardipine binding that modulated tryptophan fluorescence. Subsequent sections 
provide further insight into the function of residue 978. 
 
3.4.Location of residues contributing to vinblastine binding to P-gp 
The anticancer drug vinblastine is a vinca alkaloid and an established substrate for transport by P-
gp. Vinblastine was shown to stimulate the ATPase activity of CL-P-gp by 1.6±0.1 fold, with a 
potency of 1.8±0.2M (Table 2). Vinblastine stimulated the rate of ATP hydrolysis for each of the 
single cysteine mutant isoforms of P-gp to a similar extent (range 1.2-3.3 fold). In addition, five of 
the mutations (L65C, A311C, F336C, T769C, V982C) displayed no significant difference in the 
potency of vinblastine to stimulate ATP hydrolysis compared to CL-P-gp. The lack of any effect on 
potency suggests that the binding of vinblastine to these mutants was also unaffected. To provide 
support for this suggestion, the binding affinity was measured for several of the isoforms. CL-P-gp 
bound vinblastine with a KApp = 6.8±0.8M (Table 2), which was almost identical to the value 
obtained for L65C-P-gp (KApp = 5.9±0.5M). Similarly, the binding affinity measured by the 
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tryptophan fluorescence assay was unaffected by the F336C (KApp = 11±1M) and V982C (KApp = 
7.2±2.5M) mutations. It is likely that the lack of effect of these mutations on vinblastine 
stimulation of ATPase activity is because the residues are not located within the vinblastine binding 
site. 
In contrast, two of the cysteine mutations did cause marked effects on the interaction of P-gp with 
vinblastine. First, the M197C mutation caused a 3.7-fold reduction in potency of vinblastine to 
stimulate ATP hydrolysis with an EC50 = 6.6±1.7M (P<0.05), albeit with no change in the extent 
of stimulation (1.7±0.1 fold). To ascertain whether this alteration involved a change in vinblastine 
binding, the effects on tryptophan fluorescence were measured. The M197C-P-gp mutant also 
displayed a considerable reduction in the binding affinity for vinblastine (KApp = 21±5M, P<0.05), 
but with no effect on the maximal spectral shift. The combined effects of this mutation on the two 
reporter assays provide support for locating residue M197 in (or proximal to) the binding site for 
vinblastine. 
The F978C mutation was also associated with a significant impairment in the potency of vinblastine 
to stimulate ATP hydrolysis, with the EC50 value rising 5.1-fold to 9.2±1.8 M (P<0.05) and with 
no change in the extent of stimulation. This mutation also affected the interaction of nicardipine 
with P-gp, despite the fact that it has been established that the drug binds at a pharmacologically 
distinct site to vinblastine [7, 17]. Notably, whilst F978C was shown to affect nicardipine binding 
by the tryptophan fluorescence assay, this mutation did not affect vinblastine binding since the 
apparent binding affinity (KApp = 7.3±2.59.2±1.5M) was identical to that of CL-Pgp. The 
discriminatory effects of the mutation on vinblastine interaction with P-gp indicate that residue 
F978 is not within the drug binding site. However, the mutation did impair the coupling between 
the vinblastine binding site and the NBDs, reflected in the altered vinblastine stimulation of ATPase 
activity. 
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3.5.Location of residues contributing to rhodamine123 binding to P-gp 
Of the four drugs investigated, the rhodamine123 response was affected by the largest number of P-
gp mutations. Rhodamine123 displayed the lowest potency to stimulate ATP hydrolysis, 
characterised for CL-P-gp with an EC50 = 255±56M and a 1.8±0.2 fold increase in the basal 
activity (Table 3). The L65C (EC50 = 691±132M) and V982C (EC50 = 1181±357M) mutations 
were shown to display a statistically significant reduction in the potency of rhodamine123 to 
stimulate ATP hydrolysis. In contrast, the F336C mutation resulted in a higher potency (EC50 = 
68±8M) to stimulate ATP hydrolysis compared to the CL-P-gp isoform. The greatest effect was 
observed for the F978C mutant, which failed to elicit any stimulation of ATP hydrolysis by 
rhodamine123.  
In the case of rhodamine123, the affinity for binding was increased to >100M, in the F978C 
mutant, which reflects a marked reduction in potency of binding. However, the effect on binding 
was not as severe as the abrogation of the ability of rhodamine123 to stimulate ATP hydrolysis. The 
higher KApp value would suggest that F978 is a contact-residue for rhodamine123 binding and that 
the dramatic effect on hydrolysis reflects a central role for this residue in conformational coupling 
between the binding cavity and the NBDs. 
The other mutants that affected ATP hydrolysis were also associated with perturbation of 
rhodamine123 binding. For example, the L65C (KApp = 89±25M) and V982C (KApp = 73±13M) 
mutations resulted in an approximately 2-fold reduction in the potency of rhodamine123 binding to 
P-gp. Despite an improvement in the potency to stimulate ATP, the binding of rhodamine123 to 
F336C-P-gp was impaired. The KApp value in Table 3 was assigned a value >100M since it was 
not possible to reach sufficiently high concentrations of rhodamine123 to generate a full hyperbola 
to the binding interaction. This suggests that whilst F336C is likely to be involved in rhodamine123 
binding per se, it may also facilitate conformational changes in this binding site that couple with the 
NBDs. 
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3.6.Location of residues contributing to paclitaxel binding to P-gp 
Paclitaxel stimulated ATP hydrolysis by CL-P-gp with the greatest potency (EC50 = 0.55±0.09M) 
of the four drugs tested (Table 4) and it increased the basal activity by 2.2±0.3 fold. The degree of 
stimulation observed for the eight isoforms was in a tight range of 1.7 to 2.9-fold and none of the 
mutations altered the degree of stimulation. In addition, the L65C, M197C, F336C, T769C and 
V982C mutations all failed to alter the potency of paclitaxel to stimulate ATP hydrolysis, compared 
to the CL-P-gp isoform. Paclitaxel bound to the control CL-P-gp isoform with a dissociation 
constant of KApp = 26±6M. The binding of paclitaxel to P-gp was also unaffected by the L65C 
(KApp = 21±10M) and M197C (KApp = 15±9M) mutations, which is in agreement with their lack 
of effect on ATP hydrolysis. 
The A311C mutation in TM5 was associated with perturbation of the interaction between paclitaxel 
and P-gp. This mutation caused a 5.3-fold reduction in the potency of paclitaxel to stimulate ATP 
hydrolysis compared to the CL-P-gp control, as demonstrated by the elevated EC50 = 2.9±1.4M 
(P<0.05) (Table 4). The drug binding assay also demonstrated that the A311C mutation altered the 
interaction of paclitaxel with P-gp. In particular, the binding dissociation constant was significantly 
(P<0.05) reduced by 2.2-fold (compared to CL-P-gp) to 56±10M (Table 4). This suggests that the 
altered potency to stimulate ATP hydrolysis was caused by impaired binding of paclitaxel to P-gp 
and that residue A311 is likely to reside within the drug binding site for paclitaxel. 
The F978C mutation, once again, caused altered drug interaction as shown for paclitaxel in Table 4. 
The potency to stimulate ATP hydrolysis was significantly (P<0.05) affected, with a 7.9-fold rise in 
the EC50 value to 4.4±1.1M, when compared to the CL-P-gp control. However, unlike the A311C-
P-gp isoform, the F978C-P-gp mutation did not alter the binding affinity for paclitaxel (KApp = 
21±2M), which was not significantly different to the control (Table 4). Therefore, in a situation 
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analogous to that observed for vinblastine, the F978C mutation did not alter binding per se; 
however, it did modulate the communication between the paclitaxel binding event and the ATP 
hydrolytic machinery.  
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4. DISCUSSION 
P-gp is known to bind its vast array of substrates and inhibitors at multiple pharmacologically 
distinct sites [9, 10, 16, 17]. Until now the spatial location of these sites has remained elusive. In the 
present investigation we have identified a number of contact residues that are important in the 
binding of drugs known to interact at each of these pharmacologically distinct binding sites. This 
strategy has provided insight into the spatial separation of drug interaction sites on P-gp. Several 
mutagenesis and structural studies suggested that specific drugs bound within the central cavity of 
the TMD [19, 20, 28, 29, 33]. However, in the present investigation, three of the four drug binding 
sites had contact residues located at the lipid-protein interface and outside the central cavity. 
The locations of the contact residues for each drug are shown in the molecular model of P-gp in 
Figure 4 and support the hypothesis of pharmacologically and spatially distinct drug binding 
locations within the TMD. Four contact residues were identified for rhodamine123 and were 
localised within the central cavity, proximal to its closure (or apex) near the central plane of the 
TMD. The interactions of the modulator nicardipine, and the transport substrates vinblastine and 
paclitaxel, with P-gp were only associated with a single contact residue each. Paclitaxel interacted 
closer to the extracellular region of the TMD than the rhodamine123 site. The contact residues for 
nicardipine and vinblastine were located at the protein-lipid interface of P-gp, outside of the central 
cavity and at a more cytoplasmic location than the rhodamine123 site. 
How do our data for rhodamine123 compare with previous work on the R-site, which employed 
labelling of single cysteine isoforms of P-gp with a thiol-reactive rhodamine analogue and 
monitoring the effects on ATP hydrolysis [29]? The candidate residues identified using this 
approach were in broad agreement with those identified from docking and MD simulation based 
studies [20, 34, 35]. Another investigation using a large number of P-gp isoforms adopted a 
different approach using arginine enhancer mutations to identify residues within the translocation 
pathway [36]. However, both these investigations use a measure of overall protein activity and so 
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will likely identify residues that comprise the R-site for binding in addition to those in the 
translocation pore and involved in TMD-NBD coupling. In both studies, the residues were localised 
to TM helices lining the central cavity, with mutations in TM6 and TM12 featuring prominently 
[29, 36]. According to the murine P-gp structures many of these residues are also involved in the 
binding sites for two stereoisomers of a synthetic cyclic peptide [19]. 
The residues shown in the present investigation to mediate rhodamine123 interaction with P-gp 
(L65C, F336C, F978C, V982C) show some overlap with those described above. Our new data that 
includes direct measurement of drug binding provides strong support for the localisation of the R-
site within the central cavity near its apex that forms at the cytoplasmic leaflet of the bilayer. 
Structural data indicates that this central cavity is accessible from the cytoplasm and the inner 
leaflet of the bilayer [19, 37]. The region corresponding to the R-site contains predominantly non-
polar or aromatic amino acids and those identified in this study as contact residues for rhodamine 
binding are all hydrophobic. 
In contrast to the data for rhodamine123, the contact residues for the other three compounds were 
not found within the central cavity. These residues were located at the lipid-protein interface, which 
concurs with the “vacuum cleaner” hypothesis of P-gp mechanism whereby transported substrates 
were extracted directly from the lipid milieu. This could be predicated on a drug binding site at the 
protein-lipid interface. Supporting evidence is provided by the highly hydrophobic probe [125I]-
INA, which could only be covalently attached to P-gp in the presence of the substrate doxorubicin 
[38]. [125I]-INA is photo-activated by the chromophore doxorubicin and the cross-linking could 
only occur if the two compounds were in close proximity; namely, within the lipid milieu. These 
findings are consistent with access to substrate binding sites from the hydrophobic environment of 
the lipid bilayer, rather than via the cytoplasm as observed for ion transport proteins. 
Location of a drug binding site proximal to the lipid-protein interface of P-gp was also provided by 
an elegant photoaffinity based approach [30]. P-gp was photolabelled by the substrate propafenone 
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and then extensively digested. The resultant fractions analysed by matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry to identify those with attached propafenone. 
The most frequently modified residues were M197 (TM3), A311 (TM5), T769 (TM8) and F951 
(TM11). Molecular modelling analysis suggested that the protein contained two binding sites that 
contained M197/F951 and A311/T769 respectively. The authors suggested that these proximal TM 
helices formed “gates” to substrate entry to a central binding site and were located at the protein-
lipid interface. An alternative interpretation is that the helix pairs form distinct binding sites for 
drug association to P-gp, with subsequent movement of the drug through to a central translocation 
pore. 
Three of the four residues listed in the preceding paragraph were defined in the present study as 
contact residues for drug binding to P-gp. Unfortunately, efforts to generate the F951C mutant 
isoform did not produce recombinant baculovirus that resulted in expression of P-gp in insect cells. 
However, it was shown that vinblastine interacts with M197, nicardipine with T769 and paclitaxel 
with A311. Although different drugs were chosen between the two investigations, there is broad 
agreement with respect to the amino-acids that contribute to binding sites. The TM3/11 and TM5/8 
sites are separated by too large a distance to form a single binding site for propafenone, which is 
thus assumed to interact at two sites were suggested to provide individual binding sites for 
propafenone; in other words, propafenone can bind at two different locations on P-gp. This 
interpretation was based on the distance between TM3/11 and TM5/8 being too large to 
accommodate the binding of a single propafenone molecule to both. This is certainly not unusual 
since the P-gp substrate doxorubicin is also known to bind and more than one site [39]. The 
compounds chosen in the present investigation are more discerning in their binding sites and their 
characteristics of binding to P-gp indicate a single class of site for each. Vinblastine and nicardipine 
exhibit a complex allosteric interaction on P-gp and their binding sites are clearly distinct from a 
pharmacological perspective [7, 40]. Moreover, the two contact residues identified in the present 
investigation (T769 and M197) are spatially separated and a molecular model for P-gp (PDB4m1m) 
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predicts a separation of approximately 33Å. In addition, the two contact residues are located 
towards the cytoplasmic face of P-gp, within the inner hemi-leaflet of the membrane. In contrast, 
the contact residue for paclitaxel (A311) is located within the plane of the outer leaflet of the 
bilayer. 
Therefore, we would propose that the central cavity of P-gp contains the R-site (and the overlapping 
H-site) for drug interaction with P-gp [10] and that these sites are proximal to the “apex” or 
“closure point” for the cavity. In addition, P-gp contains alternate drug binding sites at the lipid-
protein interface, to enable extraction of drugs from the bilayer. These sites are clearly transport 
competent, particularly for vinblastine and paclitaxel whose efficacy is impaired by resistance 
conferred through P-gp expression [8]. In addition, both anticancer drugs are able to stimulate ATP 
hydrolysis, revealing that the binding sites are coupled to the NBDs. 
Do multiple, spatially distinct, binding sites equate to multiple translocation pathways, or do they 
connect to a common route? Our data on the F978C mutation imply that a common route of 
translocation exists. Mutation of F978C resulted in impaired stimulation of ATP hydrolysis for all 
drugs tested in the present investigation, but was only a contact residue for rhodamine123 within 
the central cavity R-site. The residue has also been widely implicated to reside within the 
translocation pore for a number of drugs (e.g. tariquidar, verapamil, doxorubicin, morphine) [20, 36, 
41]. Furthermore, residues proximal to F978 (A980), and within the central cavity (F343), have 
been shown by EPR-spectroscopy to undergo a shift in accessibility to a polar environment as P-gp 
switches between conformations in the transport process [42]. Another recent investigation has 
shown that F978 forms a structural motif (via hydrogen bonding to Y953) that is crucial in the 
propagation of ATP hydrolysis and the translocation process for several drugs that bind to P-gp 
with high affinity [43]. Consequently, this suggests that F978 is involved in the coupling between 
ATP hydrolysis in the NBDs with changes in the binding site for these three drugs.  
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In summary, this investigation has revealed a number of contact residues within the TMD of P-gp 
involved in binding drugs. The drugs involved were previously shown to bind at pharmacologically 
distinct sites on the protein, although their spatial relationship was unknown. The present 
investigation indicates that the site for rhodamine123 was situated within the central cavity of P-gp. 
In contrast, the sites for vinblastine and nicardipine were located at the interface between the TMDs 
and the lipid milieu. The paclitaxel binding site was located close to the central cavity, but 
embedded within the TMD. Therefore, this data demonstrates that the “pharmacologically distinct” 
sites are also spatially separated. Finally, we The residues within the central cavity were associated 
with rhodamine123 binding and the process of coupling the TMDs to the NBDs. Contact residues 
for three other drugs known to interact at pharmacologically distinct binding sites are located at the 
lipid-protein interface. We hypothesise that as P-gp switches conformational states in response to 
stimuli from the NBDs that the drugs are “relocated” to the central cavity that transitions into the 
translocation pore.  
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FIGURE LEGENDS 
 
Figure 1 Expression of mutant P-gp isoforms and purification using affinity 
chromatography 
(a) Membranes from each of the P-gp isoforms were subjected to SDS-PAGE on 8% gels in 
Laemmli sample buffer. Proteins were then transferred to nitrocellulose membrane and 
subsequently incubated with a mouse anti-histidine monoclonal antibody conjugated with 
horse-radish peroxidase. Detection of P-gp was done using chemiluminescence. Equivalent 
sample loading (20g protein) was achieved using quantitation of total protein amount. 
Lane assignments are as follows: (i) L65C, (ii) M197C, (iii) A311C, (iv) F336C, (v) 
T769C, (vi) F978C, (vii) V982C, (viii) CL and (ix) WT isoforms of P-gp 
(b) Fractions were collected at each stage of IMAC for the histidine-tagged CL-P-gp isoform 
and subjected to SDS-PAGE on 7% gels. Proteins were detected using PageBlue stain and 
an equivalent percentage (4%) of each fraction was loaded onto the gel. FT – flow through 
fraction of unbound protein; E1/E2 – elution fractions in 500mM imidazole; MW – 
molecular weight marker. The wash corresponds to fractions obtained in the washing steps 
with 20-80mM imidazole. 
 
Figure 2 The ATPase activity of purified mutant P-gp isoforms 
The Michaelis-Menten parameters for ATP hydrolysis by the CL and single cysteine containing P-
gp isoforms were determined using a colorimetric assay. The histogram shows the maximal activity 
(VMAX) for each isoform in basal (drug free; clear bars) and drug-stimulated (10M nicardipine; 
hatched bars). The horizontal lines reveal the levels of ATP hydrolysis for the basal (lower) and 
stimulated (upper) activities observed for the control CL isoform. All values represent the 
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mean±s.e.m obtained from independent purification preparations for CL-P-gp (n=12) and the single 
cysteine mutants (n=4 for each). 
 
Figure 3 ATP hydrolysis and drug binding assays for CL-P-gp 
A colorimetric assay was used to determine the ATP hydrolysis activity of P-gp isoforms as 
described in the methods. Drug binding was assessed using the endogenous tryptophan quenching 
assay. 
(a) ATPase activity (nmol min-1 mg protein-1) was measured as a function of nicardipine 
concentration. The general dose-response relationship was fitted to the data using non-
linear least squares regression. Data represent the mean±s.e.m obtained from nine 
independent preparations of CL-P-gp. 
(b) The fluorescence emission spectra were recorded for CL-P-gp from 305-450nm in the 
absence (black line) and presence of a series of nicardipine concentrations (2-35M). 
Nicardipine was added sequentially and the solid arrow indicates the progression to 
increasing concentrations. 
(c) The fluorescence emission spectra were recorded for CL-P-gp from 305-450nm in the 
absence (black line) and presence of a series of vinblastine concentrations (5-35M). 
Vinblastine was added sequentially and the solid arrow indicates the progression to 
increasing concentrations. 
(d) The extent of the shift in MAX for CL-P-gp in response to increasing concentrations of 
vinblastine was plotted as a binding isotherm. The data represent mean±s.e.m obtained 
from four independent preparations of P-gp. The hyperbolic binding isotherm was fitted to 
the data using non-linear least squares regression. 
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Figure 4 The distribution of contact residues in a homology model of P-gp 
(a) A structural model for human P-gp based on the PDB file 4m1m, with residues mutated to 
cysteine in the present manuscript annotated. 
(b) The image provides a top-view of the transmembrane helices of P-gp, with other elements of 
the protein removed for clarity. The contact residues identified to mediate drug interactions 
are annotated in the image and have been depicted in red (C-terminal half) or blue (N-
terminal half). The four “marker drugs” nicardipine (N), rhodamine123 (R), vinblastine (V) 
and paclitaxel (T) have been situated proximal to the appropriate “contact residues”.  
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